Trio Medicines Ltd (“Trio”) was founded in 2007 by HMR Ltd, London, UK, a contract research organisation, and the late Sir James Black (Nobel Laureate) who invented two classes of medicines, β-blockers and histamine H2-blockers. The original aim of Trio was to develop netazepide, a gastrin/CCK2 receptor antagonist, for clinical use.
In addition to netazepide, a gastrin/CCK2 receptor antagonist, Trio is now developing three other molecules: ceclazepide, a second gastrin/CCK2 receptor antagonist; TR4, a selective β2-adrenoceptor antagonist; and TR8, a formyl peptide receptor 2 agonist.
Hammersmith Medicines Research Ltd, which trades as HMR Ltd, is the parent company of Trio Medicines Ltd.
Trio is based in the premises of its parent company, HMR, London, UK, and uses its facilities and resources, and when necessary, its key staff.
We seek a partner for a pivotal phase 3 study of netazepide, and for further studies of ceclazepide. To date, HMR has funded and carried out all of Trio’s early clinical trials.